This paper is in the following e-collection/theme issue:

Formative Evaluation of Digital Health Interventions (2226) Autism Spectrum Disorder (ASD) (98) Anxiety and Stress Disorders (1013) mHealth for Data Collection and Research (917) mHealth for Wellness, Behavior Change and Prevention (2754)

Published on in Vol 6, No 8 (2022): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/37994, first published .
Heart Rate Variability Biofeedback to Treat Anxiety in Young People With Autism Spectrum Disorder: Findings From a Home-Based Pilot Study

Heart Rate Variability Biofeedback to Treat Anxiety in Young People With Autism Spectrum Disorder: Findings From a Home-Based Pilot Study

Heart Rate Variability Biofeedback to Treat Anxiety in Young People With Autism Spectrum Disorder: Findings From a Home-Based Pilot Study

Authors of this article:

Helen Coulter1 Author Orcid Image ;   Mark Donnelly2 Author Orcid Image ;   John Mallett3 Author Orcid Image ;   W George Kernohan2 Author Orcid Image
Article Authors Cited by (3) Tweetations (6) Metrics

    Original Paper

    1South Eastern Health and Social Care Trust, County Down, United Kingdom

    2Ulster University, Newtownabbey, United Kingdom

    3Ulster University, Coleraine, United Kingdom

    Corresponding Author:

    Mark Donnelly, BSc, PhD

    Ulster University

    Shore Road

    Newtownabbey, BT370QB

    United Kingdom

    Phone: 44 2895365135

    Email: mp.donnelly@ulster.ac.uk


    Background: People with autism spectrum disorder (ASD) frequently experience high levels of anxiety. Despite this, many clinical settings do not provide specialist ASD mental health services, and demand for professional support frequently outstrips supply. Across many sectors of health, investigators have explored digital health solutions to mitigate demand and extend the reach of professional practice beyond traditional clinical settings.

    Objective: This critical appraisal and pilot feasibility study examines heart rate variability (HRV) biofeedback as an approach to help young people with ASD to manage anxiety symptoms outside of formal settings. The aim is to explore the use of portable biofeedback devices to manage anxiety, while also highlighting the risks and benefits of this approach with this population.

    Methods: We assessed the feasibility of using home-based HRV biofeedback for self-management of anxiety in young people with ASD. We adopted coproduction, involving people with ASD, to facilitate development of the study design. Next, a separate pilot with 20 participants with ASD (n=16, 80% male participants and n=4, 20% female participants, aged 13-24 years; IQ>70) assessed adoption and acceptability of HRV biofeedback devices for home use over a 12-week period. Data were collected from both carers and participants through questionnaires and interviews; participants also provided single-lead electrocardiogram recordings as well as daily reports through smartphone on adoption and use of their device.

    Results: Pre-post participant questionnaires indicated a significant reduction in anxiety in children (t6=2.55; P=.04; Cohen d=0.99) as well as adults (t7=3.95; P=.006; Cohen d=0.54). Participant age was significantly negatively correlated with all HRV variables at baseline, namely high-frequency heart rate variability (HF-HRV: P=.02), the root mean square of successive differences in normal heartbeat contractions (RMSSD: P=.02) and the variability of normal-to-normal interbeat intervals (SDNN: P=.04). At follow-up, only SDNN was significantly negatively correlated with age (P=.05). Levels of ASD symptoms were positively correlated with heart rate both before (P=.04) and after the intervention (P=.01). The majority (311/474, 65.6%) of reports from participants indicated that the devices helped when used. Difficulties with the use of some devices and problems with home testing of HRV were noted. These initial findings are discussed within the context of the strengths and challenges of remotely delivering a biofeedback intervention for people with ASD.

    Conclusions: HRV biofeedback devices have shown promise in this pilot study. There is now a need for larger evaluation of biofeedback to determine which delivery methods achieve the greatest effect for people with ASD.

    Trial Registration: ClinicalTrials.gov NCT04955093; https://clinicaltrials.gov/ct2/show/NCT04955093

    JMIR Form Res 2022;6(8):e37994

    doi:10.2196/37994

    Keywords

    autism; anxiety; biofeedback; remote intervention; mobile phone 


    Background

    Autism is a lifelong developmental disability that affects how people communicate and interact with the world [1]. Substantial changes to how autism is understood and defined have taken place over the years since the term was initially described [2]. Autism is currently viewed as a neurodevelopmental disorder that develops in childhood, and the terms Kanner autism, Asperger disorder, childhood disintegrative disorder, and pervasive developmental disorder not otherwise specified have been replaced with the collective term autism spectrum disorder (ASD) [3]. All participants in this study had been diagnosed with ASD in specialist health service assessments clinics using standardized measures. None of the participants were diagnosed with a learning disability, and all had attended mainstream education. Although the term Asperger syndrome is still used by both clinicians and some able people with autism, the term ASD will be used throughout this paper to describe the condition.

    Approximately 1% of the British population are likely to have some form of ASD, with studies reflecting this prevalence both in children [4] and adults [5]. Epidemiological studies have shown a dramatic increase in the numbers of people being diagnosed with ASD. In the United States, the Centers for Disease Control and Prevention reported a prevalence rate of ASD in children of 1 in 88 [6], which was updated to 1 in 59 in 2018. The reasons for these apparent increases have been debated but may be related to changing definitions of the disorder, increased awareness of the condition in women, and recognition of the condition in people with no learning disability [7].

    People with ASD can experience a range of mental health difficulties [8,9] and present with high levels of anxiety [10]. A range of interventions exist to treat anxiety in ASD [11]. There is some evidence for effectiveness of nonpharmacological interventions such as cognitive behavioral therapy adapted for people with ASD [12], but availability of such interventions is limited by poor adoption rates [13] and scarcity of mental health services for people with ASD [14].

    There is evidence that digital health interventions can aid compliance with traditional treatments and help to reduce increasing demands on health provision, while extending the reach of professional practice beyond traditional clinical settings [15].

    Digital Health Interventions

    Digital solutions can be tailored to the needs of people with ASD and can be associated with less stress than that reported in face-to-face interventions [16]. Technology may be used both to deliver interventions and augment communication and social interaction [17]. Emerging digital health interventions are being investigated to help those with ASD to understand and control their reactions [18] and to help them better interpret social situations [19]. A type of intervention that has been found to reduce symptoms of anxiety in a range of populations makes use of biofeedback [20,21], which has been defined as “a self-regulation technique through which patients learn to voluntarily control what were once thought to be involuntary body processes” [22]. Biofeedback actively involves the user, enabling them to change certain physiological responses to improve health [23].

    Biofeedback

    A variety of biofeedback equipment now exists for both psychophysiological stress profile assessment [24] and for biofeedback training [23], typically categorized into two types: large professional systems and small portable devices intended for personal use. Treatment protocols exist for a wide range of physical and mental health conditions, using either a single sensor or multiple sensors with evaluations of efficacy for each condition [25].

    Although biofeedback has been used since the 1970s, there is now growing interest in its use in stress management [26]. Several systematic reviews highlight evidence supporting biofeedback as a cost-effective intervention to help manage anxiety in clinical populations [21,27]. A review of the types of biofeedback modalities and devices currently being evaluated for stress management has been carried out by Yu et al [28]. Many devices have only been tested in nonclinical populations or in laboratory environments, and the importance of testing devices in real-world situations with diverse types of clinical populations has been noted [29].

    To date, the most widespread use of biofeedback in individuals with ASD has involved the use of neurofeedback [30,31]. Recent studies show some positive effects in areas such as attention and social skills; however, systematic reviews investigating neurofeedback in ASD have not shown significant results in reducing symptoms such as anxiety [32,33]. An alternative type of biofeedback that has been used to manage anxiety has been termed resonant frequency feedback, more commonly known as heart rate variability (HRV) biofeedback [34].

    HRV Biofeedback

    HRV was first recognized 60 years ago as an indicator of fetal distress [35] and then found to be affected by breathing frequency [36]. HRV reflects the activity of both the sympathetic and parasympathetic activities of the autonomic nervous system and is reported in both time and frequency domains [37]. A review of HRV metrics has been produced [38], with population norms identified [39]. HRV is affected by age [40], the environment, breathing rate, and blood pressure, and it is subject to regulation of the autonomic nervous system [41]. HRV is frequently used as a physiological marker in stress detection [42]. It is also an index of adaptability and of the ability to self-regulate behavior [43].

    A number of theoretical models have been proposed describing the links between HRV and health, mediated through connections between the heart and the brain [44,45]. The polyvagal theory suggests that impairments in the autonomic nervous system involving vagus nerve regulation, termed the social engagement system, are features of several disorders, including ASD.

    HRV has been used in conjunction with sensor technology to develop HRV biofeedback [46,47]. Training in HRV biofeedback involves resonant frequency breathing, which has been associated with respiratory sinus arrhythmia where heart rate acceleration and deceleration rates synchronize with respiration and occur when breathing is slowed to a rate between 4.5 and 7.0 breaths per minute [41]. To support the maintenance and development of resonant frequency breathing, individuals can practice paced breathing or use portable home trainer biofeedback devices.

    Portable biofeedback devices typically derive HRV using infrared photoplethysmography (PPG), which measures blood flow, usually through either the fingertip or the earlobe. Peripheral blood flow can be used to assess heart rate and to estimate HRV [23]. Several such devices conform with health, safety, and environmental protection standards. They can be adjusted by the user to different breathing rates but are usually set at a default rate of 6 breaths per minute. Assessment of the accuracy of some devices has also been carried out [48,49]. A growing number of research studies have also now investigated their effectiveness when used as stand-alone interventions.

    There are wide variations in study design, using different devices, training protocols, and outcome measurements. Nevertheless, systematic reviews and meta-analyses have concluded that HRV biofeedback can be an effective treatment for symptoms in a range of different populations, including both adults [20,21] and children [50]. Providing interventions for symptoms such as anxiety that affect people with ASD has been emphasized as a vital area for research [51], and reviews have acknowledged the need to involve the ASD community directly in research [52,53]. HRV biofeedback has been used in a range of populations for anxiety management. To date, no studies have investigated the feasibility of using portable biofeedback devices as a home-based intervention to help people with ASD manage anxiety.

    For people with ASD, biofeedback may provide specific advantages for the management of anxiety. First, it provides a technique for developing control over specific symptoms without the need for verbally based techniques designed for non-ASD populations or behavioral interventions that may be anxiety provoking for people with ASD [54]. Second, biofeedback can present structured visual information in a systematic manner, a factor suited to the typical communication strengths of people with ASD. Third, biofeedback also aims to increase awareness of physiological reactions, which can be reduced or impaired in people with ASD [55].

    Finally, people with ASD show a range of different physiological reactions compared with non-ASD peers [56]. The different HRV responses of people with ASD have been debated [57,58]. Further investigation into interventions to help improve interoceptive ability or to develop physiological reactions may be particularly important for this population.

    Accordingly, we proceeded with an exploratory study to investigate the use of HRV biofeedback outside of clinical settings as a potential intervention to help people with ASD by reducing symptoms of anxiety.


    Overview

    The aim of this pilot and feasibility trial comprised two main objectives: first, to explore the use of HRV biofeedback as a suitable methodology to support people with ASD to manage anxiety outside of clinical settings and, second, to assess the risks, benefits, and challenges of using HRV biofeedback within this population.

    We involved adults with ASD and professionals working in the field in the initial study development and design. We then recruited a separate group of young people with ASD in an experimental design with appropriate pre- and postintervention outcome measures.

    We recorded demographic data and mental health status and used participant anxiety and depression as the primary outcome measures. Statistical analyses were carried out to assess mean group differences in reported anxiety and depression. A per-protocol analysis was used. This led to several participants being excluded after randomization because they met the exclusion criteria, and their pre-post data were therefore not included in the quantitative data analysis. The pre-post data sets were analyzed using a standard statistical package (SPSS software [version 24.0; IBM Corp]). Correlational analyses were also used to review associations between baseline measurements and HRV data.

    To assess the risks, benefits, and challenges we used several methods of data collection, including daily monitoring of device use, perceived participant stress levels using a questionnaire delivered through smartphone, standardized interviews, and short debriefing reports. Participants who dropped out early or had continuing difficulties using their biofeedback device or had electrocardiogram (ECG) recording difficulties after randomization had their monitoring data included for further analysis, provided that they had consented for these data to be collected. The aim of the study was to ensure methodological robustness and feasibility, with a focus upon potential risks, problems, or difficulties as well as potential benefits of using HRV biofeedback.

    Participants

    The sample was drawn from a population of patients with an existing diagnosis of ASD who had attended regional health services for help with anxiety. The young people with ASD were invited to participate in experimental adoption of a portable HRV biofeedback device over a 12-week period. All participants in this study had been diagnosed with ASD in specialist health service assessments clinics using standardized measures. None had a learning disability, and all had attended mainstream education. Additional preassessment screening of participants was carried out using the Social Communication Questionnaire [59], yielding a mean score of 20, which is above the cutoff level for diagnosis of ASD. Participants were excluded if they had pre-existing addiction; a diagnosed cardiac condition; a learning disability; or where suicidal risk, psychosis, or severe eczema or psoriasis had been noted; or if they were taking medications known to suppress HRV, such as benzodiazepines or tricyclic antidepressants [60]. All participants received appropriate information about the study and gave consent or assent in addition to consent from a parent or carer. No incentives were offered for participation.

    Ethics Approval

    Ethics approval was granted by the regional National Health Services ethics committee (15/NI/0255; IRAS: 139122). After review by the regional National Health Services ethics committee, approval was granted under the UK governance arrangements for research ethics committees.

    Recruitment

    Potential participants were recruited using two methods: either through direct contact with their therapist or through letters sent to patients who were already discharged. It was not possible to determine the exact reasons for nonparticipation in the study because of the ethical constraints regarding contacting those who declined to participate through their therapist or those who did not respond to the invitation letters. Initially, 20 people took part: 16 (80%) male participants and 4 (20%) female participants. Their ages ranged from 13 to 22 (mean 16.2, SD 2.63) years. Detailed demographic information is presented in Multimedia Appendix 1 [61], and participant flow through the study is presented in Figure 1.

    ‎
    Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram summarizing the processes adopted for screening and enrollment, allocation into groups, follow-up, and final analysis. Participant numbers are provided for each stage.
    View this figure

    Randomization

    To decrease the risk of group allocation bias, random assignment to treatment group or control group was carried out after all preintervention assessments; therefore, the researcher was initially blind to who was allocated to each group during all baseline assessments.

    Allocation was made in blocks to ensure that adequate numbers of participants were allocated to each condition. A randomized number sequence was generated through computer.

    Between-group comparisons were planned to compare 6 weeks of intervention in the immediate group with 6 weeks of no intervention in the delayed group. The small sample size and additional exclusions from the study prevented these comparisons from being carried out.

    Equipment

    HRV home trainer devices differ in terms of form, feedback mechanisms, data storage, training guidelines, and underlying software, all of which may affect user experience and effectiveness. For this study, biofeedback devices were selected based on evidence of their use in previous research. To explore whether these aspects were of any concern, participants were allocated to 1 of 2 different biofeedback devices (Figure 2).

    Group A participants were provided with a home trainer biofeedback device that used PPG ear sensors [62]. Group B participants were provided with a home trainer biofeedback device that used a fingertip PPG sensor contained within a stand-alone device [63]. A wireless single-lead ECG recorder, worn on the chest, was used to measure participant heart rate and HRV from a single lead before and after the intervention [64]. This lightweight device is battery powered and does not require any external leads or Velcro to connect to the recorder.

    ‎
    Figure 2. We used 2 personal home trainer devices to provide biofeedback during pilot testing: StressEraser, left, and Inner Balance, right (Inner Balance image reproduced with permission of HeartMath).
    View this figure

    Measures

    Participants were invited to complete anxiety and depression questionnaires before and after the intervention. The measures included Beck Anxiety Inventory [65], Beck Depression Inventory-II [66], and Beck Youth Inventories-II for people aged 13 to 17 years [67] as appropriate to age. The parent or family carer was also invited to complete short before-and-after interviews, rating any changes in participant behavior over the course of the intervention period.

    During the intervention period, participants were asked to complete short daily reports on stress levels and device use. This enabled us to track participant stress levels and monitor perceived usefulness of the device. The progress report was devised based on initial phase 1 evaluations and served a 2-fold purpose: tracking participant stress levels and monitoring use of the device over the course of the intervention. This short report asked questions on sources of stress, levels of stress, and use of the biofeedback device.

    At the end of the intervention, participants and carers independently completed a short debriefing interview, and participants completed equipment usability ratings using the System Usability Scale [SUS]. This questionnaire provides a standardized assessment of the usability of different technology products [68]. The scale comprises 10 short statements rated on a 5-point scale. Item scores are summated and then rescaled in the range from 0 to 100, with higher scores indicating higher usability. Empirical evaluations of the SUS indicate good reliability [69]. A summary of the measures used is provided in Multimedia Appendix 2 [70,71,65,66,67,72,73,68].

    Intervention

    All participants were offered initial assessment and training in their own home, with their carer present. This was carried out by a chartered clinical psychologist with certified training in HRV biofeedback (HC). The training involved sending video clips and written instructions produced by the device manufacturers to participants before an agreed home visit in which a direct demonstration of device use was given. Participants were then all seen and assessed by the first author (HC) who offered 2 training sessions (lasting for 30 minutes each) of home instruction in use of the allocated biofeedback device. No other intervention regarding anxiety management was provided. The HRV biofeedback intervention was available to use daily for a period of 12 weeks. Self-tailoring of intervention intensity was allowed to gauge acceptability and record self-reported compliance. Use was encouraged by the first author (HC) at the outset and indirectly through monitoring uptake. Information on participant anxiety and depression was collected through questionnaire measures completed before and after the intervention.

    Participant HRV was measured in the home through a psychophysiological stress profile assessment using a single-lead ECG recorder before and after the intervention. Once the intervention commenced, remote monitoring continued daily, using SMS text message prompting at preset intervals agreed with participants. Questions used to monitor use of the intervention were sent to participants at an agreed time in the evening, recording whether they had used the device that day and whether it had been perceived as useful. Finally, additional information on risks, perceived problems, and benefits of the intervention and equipment usability was collected in face-to-face interviews with participants and their carers at the end of the intervention. This information was also collected from those who dropped out and those whose pre-post data were excluded, provided they consented to provide these data. This was seen as crucial to capture information on any potential difficulties and ensure a representative assessment of risks and benefits. Further details on the intervention are presented in the CONSORT (Consolidated Standards of Reporting Trials) and Template for Intervention Description and Replication checklists (Multimedia Appendices 3 and 4) and the study protocol (Multimedia Appendix 5 [68,74,75,76,64,77,73,78,79,24,80,81,82]).


    Demographic Information

    All participants were nonsmokers, and none reported taking illegal drugs. Of the 20 participants, 10 (50%) reported prescribed medication. Of these 10 participants, 6 (60%) were prescribed selective serotonin reuptake inhibitor antidepressants, and 4 (40%) took stimulant medication. Sleep disturbance was reported by 75% (15/20) of the participants; 15% (3/20) reported needing to carry auto injectors with adrenaline (EpiPen). Of the 20 participants, 16 (80%) were employed or were students.

    Carers were asked standardized questions regarding their main concerns about participant behavior, including whether there were any triggers for participant anxiety attacks or meltdowns and any strategies used to manage anxiety. The main concern reported was anxiety. The main triggers for anxiety attacks reported by 70% (14/20) of the families were sensory issues such as “loud noise,” “bright lights,” or “touch”; other triggers reported were “changes in routine” and increases in workload or examinations. Busy or crowded places, for example, “shopping centers” or school, were also mentioned as frequent triggers for anxiety by 55% (11/20) of the families. The most frequently reported strategy to help manage anxiety described by 85% (17/20) of the families involved reducing sensory information; for example, “reduce noise” or “turn down lights.” Other strategies reported were engaging in favorite activities or physical activity, spending time with parent or carer or pet, listening to music, and escaping from the source of stress by fighting or running away. All carers and participants reported more than one strategy for managing anxiety.

    Participant Anxiety and Depression

    Of the 20 participants, 4 (20%) were excluded after randomization because of the identification of cardiac concerns (n=3, 75%) and significant mental health concerns (n=1, 25%), whereas 1 (5%) dropped out and declined further questionnaire and physiological assessment, leaving 15 participants (n=11, 73%, male participants and n=4, 27%, female participants) for before-and-after data analysis (Figure 1).

    Statistical analyses were carried out using SPSS software (version 24.0) to assess mean group differences in reported anxiety and depression. Parametric statistical tests were conducted using paired sample 2-tailed t tests. Anxiety scores at baseline did not deviate from normality on either the Kolmogorov-Smirnov test (P=.20) or the Shapiro-Wilk test (P=.23). As different measures were necessarily used for children and adults, separate analyses were performed for these groups.

    Of the 15 participants, 1 (7%) adult participant did not complete the initial depression questionnaires: 14 sets of depression data were analyzed. Parametric statistical tests were also conducted using paired sample 2-tailed t tests. Again scores at baseline did not deviate from normality on either the Kolmogorov-Smirnov test (P=.20) or the Shapiro-Wilk test (P=.78).

    Data collected from children and adults showed statistically significant reductions in mean score for anxiety after the intervention; the results for both adults and children showed no significant reduction in mean scores for depression (Table 1).

    Table 1. Participant questionnaire data showing mean scores for anxiety and depression before and after using heart rate variability biofeedback (N=15).
    Participants (aged 13-24 years)Before the intervention, mean (SD)After the intervention, mean (SD)Mean difference (SD)Coefficient, rt test (df)P value (2-tailed)Cohen d (adjusted)
    Anxiety

    		BYI-Aa (children: n=7)24.43 (8.98)14.43 (10.97)10.00 (10.39)0.4722.55 (6).040.99

    		BAIb (adults: n=8)21.12 (11.2)15.00 (11.49)6.12 (4.39)0.9253.95 (7).0060.54
    Depression

    		BYI-Dc (children: n=7)20.43 (14.04)13.71 (14.16)6.71 (9.53)0.0771.86 (6).110.48

    		BDId (adultse: n=7)17.0 (12.74)13.86 (10.91)3.14 (4.85)0.9281.72 (6).140.25

    aBYI-A: Beck Youth Inventory, Anxiety scale.

    bBAI: Beck Anxiety Inventory.

    cBYI-D: Beck Youth Inventory, Depression scale.

    dBDI: Beck Depression Inventory.

    eAn adult participant did not complete the depression questionnaire.

    Carer Reports on Behavior

    Carers were asked to rate the frequency of participant behavioral outbursts or meltdowns at the initial and debriefing interviews. Carer ratings indicated a significant reduction (Wilcoxon signed-rank test) in the frequency of behavioral outbursts comparing initial interview data with debriefing interview data (Z14=–3.33; P=.001; r=0.6).

    ECG Assessment

    Attempts were made to record wireless ECG data to detect changes in HRV over time using a psychophysiological stress test [24] before and after the intervention, but it was not possible to standardize this procedure because of the wide variations in the timing of assessments, differing home environments, and the use of HRV data from both children and adults. However, baseline ECG recordings did enable within-subject comparisons. Pearson bivariate correlations compared heart rate and HRV variables with age and level of ASD symptoms (Table 2). Before the intervention, age was significantly negatively correlated with all HRV variables at baseline, namely high-frequency heart rate variability (P=.02), the root mean square of successive differences in normal heartbeat contractions (P=.02) and the variability of normal-to-normal interbeat intervals (P=.04). ASD symptoms were positively correlated with heart rate both before (r=0.54; P=.04) and after the intervention (r=0.74; P=.001), and negatively correlated with HF HRV recorded at the final assessment (r=–0.56; P=.03). In addition, HRV indices were negatively correlated with heart rate both before and after the intervention.

    Table 2. Pearson bivariate correlation statistics before and after the intervention between physiological measures of heart rate and heart rate variability recorded with participant age and level of ASD (autism spectrum disorder) symptoms as measured by the Social Communication Questionnaire [59].

    		AgeASDHF-HRVaRMSSDbSDNNcHRd
    Age

    		Before the intervention1–0.250–0.580e–0.596e–0.548e–0.001

    		After the intervention—f—–0.389–0.381–0.522e–0.062
    ASDg

    		Before the intervention—1–0.221–0.134–0.1840.541e

    		After the intervention——–0.557e–0.442–0.504e0.743h
    HF-HRV

    		Before the intervention——10.929h0.902h–0.562e

    		After the intervention———0.892h0.905h–0.733h
    RMSSD

    		Before the intervention———10.946h–0.514e

    		After the intervention————0.910h–0.616e
    SDNN

    		Before the intervention————1–0.465

    		After the intervention—————–0.694h
    HR

    		Before the intervention—————1

    		After the intervention——————

    aHF-HRV: high-frequency heart rate variability (a frequency domain index that can indicate parasympathetic nervous system activity).

    bRMSSD: root mean square of successive differences in normal heartbeat contractions or interbeat intervals measured in milliseconds (a time domain heart rate variability index that can be associated with parasympathetic nervous system activity).

    cSDNN: SD of the normal heartbeat contractions; that is, normal-to-normal interbeat intervals measured in milliseconds.

    dHR: heart rate measured in beats per minute.

    eP<.05 (2-tailed).

    fNot applicable.

    gAutism spectrum disorder symptomatology measured using the Social Communication Questionnaire [59].

    hP<.01 (2-tailed).

    Adoption of Biofeedback Device During Intervention

    Across the study, 474 web-based surveys were collected providing data on sources of stress and use of biofeedback devices throughout the intervention period. Participants who had difficulties using their biofeedback device or ECG recorder had their monitoring data included, provided they had consented.

    Participants were asked during the intervention period whether the device had helped them when used. The majority (311/474, 65.6%) of the reports provided indicated that the biofeedback device had been used and that “it helped” when used. Only 4% (19/474) of the reports indicated that the device “didn’t help” when used. Regarding use, 88% (417/474) of the reports indicated that the device had been used for between 0 and 10 minutes, with 12% (57/474) of the reports indicating that the device had been used for >10 minutes.

    Participants were also asked to report the reasons for not using the device. A summary of 144 reports provided by participants detailing a range of reasons is presented in Table 3.

    Table 3. Participant reported effect of biofeedback device when used (n=144).
    Reported reason for not using deviceResponses, n (%)
    “Not stressed” today65 (45.1)
    No clear reason given24 (16.7)
    “Busy” or “away”20 (13.9)
    “Device not with me”17 (11.8)
    “Forgot to use”9 (6.2)
    “Practicing later”6 (4.2)
    “Error on device”3 (2.1)

    The most frequent reason reported for not using the device was simply that the participant did not feel stressed. Other reasons reported were “too busy” (20/144, 13.9%), “device not with me” (17/144, 11.8%), “forgot to use it” (9/144, 6.3%), “practicing the device later” (6/144, 4.2%), and “error on device” (3/144, 2.1%). Of all reports submitted, 16.7% (24/144) offered no clear reason for not using the device.

    Equipment Usability

    Usability ratings were captured on the 2 biofeedback devices, an ECG recorder, and a web-based survey (Table 4). The benchmark for the SUS is 68, with scores above this value considered to be acceptable [83]. Average ratings for the equipment used in this study indicated good usability.

    Table 4. Participant ratings of 2 types of biofeedback devices, an electrocardiogram (ECG) recorder, and SMS text monitoring using the System Usability Scale (SUS) [68].
    Type of equipment usedaSUS score, mean (SD; range)Benchmark SUS scoreb, mean (SD)
    StressEraser (n=9)76.60 (16.25; 47.5-92.5)68 (12.5)
    Inner Balance (n=9)83.61 (8.94; 70.0-92.5)68 (12.5)
    Actiwave ECG recorder (n=9)70.00 (7.80; 60.0-77.5)68 (12.5)
    SMS text message survey (n=15)78.50 (9.05; 65.0-100.0)68 (12.5)

    aA total of 18 ratings of biofeedback devices were completed: 9 for StressEraser and 9 for Inner Balance; 9 ratings were completed regarding the electrocardiogram recorder; and 15 ratings were completed regarding the SMS text message report.

    bBenchmark calculation of average SUS scores [83].

    Risks and Benefits

    During the debriefing at the end of the study, participants and carers reported perceived benefits and any problems. Unexpectedly, many of the participants reported cold fingers during initial training, with 70% (7/10) of those initially allocated to the StressEraser reporting difficulty using this device at some point during the study.

    Clinical disclosures included previously unrecognized cardiac irregularities (3/20, 15%) and severe mental health difficulties (1/20, 5%). These were identified after enrollment after initial screening.

    A range of positive benefits were reported by both participants and their carers, with the most frequent benefit reported being feeling calm or relaxed. A smaller number of problems were reported overall, mainly relating to difficulties with the fingertip sensor device. The results presented in Tables 5 and 6 show the frequency counts of key phrases reported in debriefing reports from participants.

    Table 5. Participant reported problems of using biofeedback device (n=24).
    Reported problemsResponses, n (%)
    Finger sensor errors5 (21)
    Difficulty using while stressed5 (21)
    Lack of practice4 (16)
    Device functions difficult3 (13)
    Needed reminders3 (13)
    Didn’t find it helped2 (8)
    Ear sensor difficulty2 (8)
    Table 6. Participant reported benefits of using biofeedback device (n=43).
    Reported benefitsResponses, n (%)
    Felt calm or helped11 (25)
    Ease of use9 (21)
    Helped breathing5 (11)
    Helped sleep4 (9)
    Good video tutorials provided3 (7)
    Visual or can “see” results3 (7)
    Helped when not using2 (5)
    Helped focus2 (5)
    Portable2 (5)
    Efficient2 (5)

    Principal Findings

    This pilot study highlights potential positive effects of HRV biofeedback in people with ASD, with fewer symptoms of anxiety being reported after using HRV biofeedback devices at home. Carers also reported fewer behavioral meltdowns. Remote monitoring indicated that although most (417/474, 88%) of the participants only used the device for short periods of time (0-10 minutes), the majority (311/474, 65.6%) indicated that the device helped when it was used. Notably, only 4% (19/474) of the reports highlighted instances where the device did not help. However, difficulties surrounding the usability of the finger-type sensor device were reported.

    A perceived strength of this study was the experimentation of a new intervention in a population where there is high need and where little research exists on issues that affect the lives of people with ASD [84]. A further strength was the assessment of people with ASD by embedding self-reporting in place of traditionally used carer reports. Indeed, self-reports from young people with ASD can be reliable over time [85], and the use of remote monitoring, self-report questionnaires, and debriefing reports from participants combined with carer reports adds strength to the validity of the study findings. Overall, the findings confirmed that youngpeople with ASD can independently use portable HRV biofeedback devices, and such devices seem to help them manage anxiety.

    We note the discovery of previously undetected cardiac irregularities and deteriorating mental health. This highlights the mental and physical health vulnerabilities in this population [86,87] and the importance of providing them with both assessment and ongoing support. Pre- and postintervention data also indicated that a child participant and an adult participant showed increases in anxiety after the intervention. The debriefing reports indicated that usability issues with the device may have increased anxiety. The unforeseen instances of participants presenting with cold fingers, which affected the quality of the signal acquisition using the PPG finger sensor integrated into the StressEraser, was an unexpected finding. Cold fingers in some individuals have previously been correlated with a shutdown in peripheral circulation as a result of stress [88]. Equipment checks did not indicate any fault with the equipment, and this device has previously been used successfully in several other populations [89,90]. These difficulties highlight the importance of personalizing digital health solutions to promote use and adoption alongside the need for ongoing clinical support when problems occur. Although the StressEraser is no longer being marketed, other devices using finger sensors may need to be used with caution in people with ASD.

    Limitations

    Several limitations are acknowledged in this pilot study. A necessary limitation was the small sample size and the inherent risk of error and bias when using self-report measures. It was not possible to determine the exact reasons for nonparticipation in the study because of the ethical constraints regarding contacting those who declined to participate. All participants contacted had already attended services for anxiety. It may be that those who did not participate were not now experiencing problems with anxiety or that they were concerned about participating in research into an untested intervention. Future studies should address this issue to further assess whom this treatment might be beneficial for.

    It is possible that reductions in self-reported anxiety may have been related to other outside factors or to nonspecific therapeutic variables. However, it is of note that no time was spent with participants talking about their anxiety or providing any other type of intervention—the training given only involved a review of existing instruction guidelines in the use of each biofeedback device. It is also possible that unconscious bias may have occurred within carer interviews and participant reports because of a wish for the treatment to succeed; however, the debriefing reports indicated that several participants and their carers did report at the end of the intervention that the device did not help despite their initial hopes that it would be beneficial, and participant reports and carer reports were in concordance regarding the changes noted.

    This study attempted to carry out before-and-after HRV assessment analysis by means of a single-lead ECG recorder using a psychophysiological stress test within participants’ homes. This type of test paradigm assessment proved unsuccessful because of the lack of standardized test conditions inherent within multiple home environments. This type of stress assessment is one which is unlikely to be useful outside of clinical settings. Before embarking on home intervention programs, future interventions using physiological monitoring such as ECG assessments may require an initial clinic appointment to carry out full mental and physical health checks [75].

    In addition, individuals with ASD have also been found to exhibit both hyperarousal and hypoarousal responses to stress tasks, suggesting that the classic paradigm of a stress profile assessment designed for non-ASD populations is unlikely to provide a clear picture when used in people with ASD [56,91]. Recent research has suggested that it is preferable to carry out a longer assessment to obtain more accurate information on HRV, particularly in relation to psychological stress [92]. Because of the mental health difficulties and physiological differences observed in many people with ASD, this type of longer-term monitoring could be particularly valuable.

    Usability assessment indicated that both ECG monitoring and remote smartphone monitoring of stress levels were found to be acceptable in people with ASD. Small wireless ECG monitors can now be used for 24-hour recordings, and the approach of remote stress monitoring combined with longer ECG recordings could be used in future studies to provide much needed data on anxiety and the physiological profile of people with ASD.

    Comparison With Prior Work

    A review of HRV biofeedback studies [93] concluded that, although positive outcomes are reported in many studies, there is not always concordance between questionnaire reports and physiological measurements, and the exact mechanisms of the effect underlying HRV biofeedback have been debated [46]. Our findings suggest that there may be anxiety reduction through use of smaller portable HRV biofeedback devices, but further research using standardized physiological assessments is needed to establish whether this has any long-term effect on underlying participant HRV.

    Importantly, some participants in this pilot may not have been able to develop the specific type of resonant frequency breathing using home trainer biofeedback devices, which is argued to increase HRV [94]. The use of multichannel biofeedback equipment may be important for initial training sessions to increase HRV levels; however, for the large numbers of people now requiring intervention, this would require significant outlays in terms of time, training, and resources. Future studies could carry out initial psychophysiological monitoring in a controlled clinic setting and then provide participants with wearable technologies for home use.

    This preliminary work has provided vital information for further studies, which could now test effectiveness of HRV biofeedback for home-based remote management of anxiety in an adequately powered randomized trial using a comparator intervention with matched intervention time. This approach was used with non-ASD populations in 2 recent studies that reported positive effects from biofeedback in comparison with control interventions, such as mindfulness and walking [90,95].

    Studies investigating comparative interventions could use a breathing pacer app for smartphone use, which could assess paced breathing alone in comparison with HRV biofeedback. Future investigations should capture device data, enabling information to be gathered regarding length and type of breathing practice, which may help to address questions relating to any dose-response relationship for HRV biofeedback. Finally, this initial study only targeted young people aged 13 to 24 years with no known learning disability. A key step in further work will be to assess this methodology and intervention in other groups of people with ASD, such as older adults and people with intellectual disability.

    Conclusions

    ASD is now a common condition. Reports suggest high costs of supporting people with ASD; yet, little research has been undertaken into new types of interventions specifically designed to meet their needs [51].

    Conditions such as ASD pose a significant cost to individuals, health care providers, and society as a whole [96]. Since the data were collected, limited access to interventions for mental health conditions such as anxiety has been exacerbated by health service imperatives to address the COVID-19 pandemic. It has been argued that the current health crisis demands a “digital mental health revolution” [97]. Digital health can provide important tools to help reduce the burden of mental illness and intervene with increasing numbers of people whom traditional models of face-to-face therapy cannot support [98].

    Digital technology may represent a useful method of engaging people with ASD by using some of their characteristic strengths and interests, without the complex social and communication demands of traditional cognitive and behavior therapies [54] and without the potential risks of medication.

    The application of home-based solutions to difficulties experienced by people with ASD also represents what has been termed a “naturalistic developmental behavioral intervention” that can help with the generalization of skills because of their use in real-world interactions [99]. Methods of remote monitoring to assess the symptoms as well as the effectiveness of interventions such as biofeedback may be useful for people with ASD, which should be trialed. These techniques may also assist practitioners striving to provide personalized connected health ASD intervention support at a distance.

    Systematic reviews have outlined developments in biofeedback across a range of modalities as well as some of the challenges to be addressed in future investigations [28]. HRV biofeedback may be an important adjunct to existing interventions for non-ASD populations with mental health conditions [100,101], and people with ASD should not be excluded from developments in this area. Despite the limitations, this study provides preliminary information on the use, risks, and perceived benefits of HRV biofeedback for anxiety in people with ASD. Importantly, the direct reports from both participants and their carers provide a unique insight into the risks and difficulties as well as the potential benefits of this intervention. Although the exact mechanism of the effect remains unclear, our findings suggest that further research is warranted to clarify its effectiveness.

    Acknowledgments

    HC was supported by a Health & Social Care Doctoral Fellowship (2013-2018) from the R&D Division of the Public Health Agency, Northern Ireland, United Kingdom. The authors wish to offer thanks to Professor Richard Gevirtz, Alliant University, for his help and guidance; Assistant Professor Keri Heilman, University of North Carolina, for her advice on assessment; and Dr Cathal Breen, Ulster University, for his help with electrocardiogram recording. This study would not have been possible without the direct and forthright contributions of people with autism spectrum disorder and the support of South Eastern Health and Social Care Trust.

    Authors' Contributions

    HC was responsible for the conception of this study. HC, MD, and WGK were responsible for the study design. HC and MD drafted the article, which was critically revised by all the other authors. HC was responsible for data collection and for clinical evaluations. HC, MD, and JM were responsible for data analysis.

    Conflicts of Interest

    None declared.

    ‎
    Multimedia Appendix 1

    Participant demographic information.

    DOCX File , 20 KB
    ‎
    Multimedia Appendix 2

    Measures.

    DOCX File , 21 KB
    ‎
    Multimedia Appendix 3

    CONSORT (Consolidated Standards of Reporting Trials) 2010 checklist of information to include when reporting a randomized trial.

    DOCX File , 24 KB
    ‎
    Multimedia Appendix 4

    The Template for Intervention Description and Replication checklist.

    DOCX File , 32 KB
    ‎
    Multimedia Appendix 5

    Study protocol.

    DOCX File , 134 KB
    1. What is Autism? National Autistic Society.   URL: https://www.autism.org.uk/advice-and-guidance/what-is-autism [accessed 2022-04-01]
    2. Kanner L. Autistic disturbance of affective contact. The Embryo Project Encyclopedia. 1943.   URL: https:/​/embryo.​asu.edu/​pages/​autistic-disturbances-affective-contact-1943-leo-kanner#:~:text=In%20%22Autistic%20 Disturbances%20of%20Affective,of%20language%2C%20among%20other%20behaviors [accessed 2014-01-12]
    3. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Virginia, United States: American Psychiatric Association; 2013.
    4. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006 Jul;368(9531):210-215. [CrossRef]
    5. Brugha TS, McManus S, Bankart J, Scott F, Purdon S, Smith J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 2011 May 02;68(5):459-465. [CrossRef] [Medline]
    6. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease ControlPrevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012 Mar 30;61(3):1-19 [FREE Full text] [Medline]
    7. Thurm A, Swedo SE. The importance of autism research. Dialogues Clin Neurosci 2022 Apr 01;14(3):219-222. [CrossRef]
    8. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008 Aug;47(8):921-929. [CrossRef]
    9. Mattila M, Hurtig T, Haapsamo H, Jussila K, Kuusikko-Gauffin S, Kielinen M, et al. Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study. J Autism Dev Disord 2010 Sep 23;40(9):1080-1093. [CrossRef] [Medline]
    10. van Steensel FJ, Heeman EJ. Anxiety levels in children with autism spectrum disorder: a meta-analysis. J Child Fam Stud 2017 Mar 20;26(7):1753-1767 [FREE Full text] [CrossRef] [Medline]
    11. Anxiety in Children and Adolescents with Autism Spectrum Disorder Evidence-Based Assessment and Treatment. Amsterdam: Elsevier Science; 2017.
    12. Perihan C, Burke M, Bowman-Perrott L, Bicer A, Gallup J, Thompson J, et al. Effects of cognitive behavioral therapy for reducing anxiety in children with high functioning ASD: a systematic review and meta-analysis. J Autism Dev Disord 2020 Jun 27;50(6):1958-1972 [FREE Full text] [CrossRef] [Medline]
    13. Dingfelder H, Mandell DS. Bridging the research-to-practice gap in autism intervention: an application of diffusion of innovation theory. J Autism Dev Disord 2011 May;41(5):597-609 [FREE Full text] [CrossRef] [Medline]
    14. Cooper K, Loades M, Russell A. Adapting psychological therapies for autism - therapist experience, skills and confidence. Res Autism Spectr Disord 2018 Jan 01;45:43-50 [FREE Full text] [CrossRef] [Medline]
    15. Valencia K, Rusu C, Quiñones D, Jamet E. The impact of technology on people with autism spectrum disorder: a systematic literature review. Sensors (Basel) 2019 Oct 16;19(20):4485 [FREE Full text] [CrossRef] [Medline]
    16. 10 technologies transforming autistic lives. AUTISTIC & Unapologetic.   URL: https://autisticandunapologetic.com/2019/09/14/10-technologies-transforming-autistic-lives/ [accessed 2020-12-16]
    17. Bölte S, Golan O, Goodwin MS, Zwaigenbaum L. What can innovative technologies do for Autism Spectrum Disorders? Autism 2010 May 30;14(3):155-159. [CrossRef] [Medline]
    18. Torrado JC, Gomez J, Montoro G. Emotional self-regulation of individuals with autism spectrum disorders: smartwatches for monitoring and interaction. Sensors (Basel) 2017 Jun 11;17(6):1359 [FREE Full text] [CrossRef] [Medline]
    19. Daniels J, Schwartz JN, Voss C, Haber N, Fazel A, Kline A, et al. Exploratory study examining the at-home feasibility of a wearable tool for social-affective learning in children with autism. NPJ Digit Med 2018 Aug 2;1(1):32 [FREE Full text] [CrossRef] [Medline]
    20. Goessl VC, Curtiss JE, Hofmann SG. The effect of heart rate variability biofeedback training on stress and anxiety: a meta-analysis. Psychol Med 2017 May 08;47(15):2578-2586. [CrossRef]
    21. Lehrer P, Kaur K, Sharma A, Shah K, Huseby R, Bhavsar J, et al. Heart rate variability biofeedback improves emotional and physical health and performance: a systematic review and meta analysis. Appl Psychophysiol Biofeedback 2020 Sep 08;45(3):109-129 [FREE Full text] [CrossRef] [Medline]
    22. Frank D, Khorshid L, Kiffer JF, Moravec CS, McKee MG. Biofeedback in medicine: who, when, why and how? Ment Health Fam Med 2010 Jun;7(2):85-91 [FREE Full text] [Medline]
    23. Biofeedback Mastery An Experiential Teaching and Self-Training Manual. Wheat Ridge, Colorado, United States: Association for Applied Psychophysiology and Biofeedback; 2008.
    24. Matto D. The added advantage of the psychophysiological stress profile. Psychophysiol Today 2013;8(1):5 [FREE Full text] [CrossRef]
    25. Evidence-based Practice in Biofeedback & Neurofeedback 3rd Edition. Wheat Ridge, Colorado, United States: Association for Applied Psychophysiology and Biofeeback; 2016.
    26. Kennedy L, Parker SH. Biofeedback as a stress management tool: a systematic review. Cogn Tech Work 2018 May 29;21(2):161-190. [CrossRef]
    27. Schoenberg PL, David AS. Biofeedback for psychiatric disorders: a systematic review. Appl Psychophysiol Biofeedback 2014 Jun 8;39(2):109-135. [CrossRef] [Medline]
    28. Yu B, Funk M, Hu J, Wang Q, Feijs L. Biofeedback for everyday stress management: a systematic review. Front ICT 2018 Sep 7;5 [FREE Full text] [CrossRef]
    29. Kyriakou K, Resch B, Sagl G, Petutschnig A, Werner C, Niederseer D, et al. Detecting moments of stress from measurements of wearable physiological sensors. Sensors (Basel) 2019 Sep 03;19(17):3805 [FREE Full text] [CrossRef] [Medline]
    30. Friedrich EV, Suttie N, Sivanathan A, Lim T, Louchart S, Pineda JA. Brain-computer interface game applications for combined neurofeedback and biofeedback treatment for children on the autism spectrum. Front Neuroeng 2014 Jul 03;7:21 [FREE Full text] [CrossRef] [Medline]
    31. Datko M, Pineda JA, Müller RA. Positive effects of neurofeedback on autism symptoms correlate with brain activation during imitation and observation. Eur J Neurosci 2018 Mar 27;47(6):579-591. [CrossRef] [Medline]
    32. Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S. Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 2011 Nov;53(11):986-993 [FREE Full text] [CrossRef] [Medline]
    33. Kouijzer ME, van Schie HT, Gerrits BJL, Buitelaar JK, de Moor JM. Is EEG-biofeedback an effective treatment in autism spectrum disorders? A randomized controlled trial. Appl Psychophysiol Biofeedback 2013 Mar 18;38(1):17-28. [CrossRef] [Medline]
    34. Vaschillo EG, Vaschillo B, Lehrer PM. Characteristics of resonance in heart rate variability stimulated by biofeedback. Appl Psychophysiol Biofeedback 2006 Jun 13;31(2):129-142. [CrossRef] [Medline]
    35. The classification of fetal heart rate. In: The Medicalization of Obstetrics. Milton Park, Abingdon-on-Thames, Oxfordshire, England, UK: Routledge; 1996.
    36. Angelone A, Coulter NA. Respiratory sinus arrhythmia: a frequency dependent phenomenon. J Appl Physiol 1964 May 01;19(3):479-482. [CrossRef]
    37. Malik M, Bigger JT, Camm AJ, Kleiger RE, Malliani A, Moss AJ, et al. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Euro Heart J 1996 Mar 01;17(3):354-381. [CrossRef]
    38. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health 2017 Sep 28;5:258 [FREE Full text] [CrossRef] [Medline]
    39. Dantas EM, Kemp AH, Andreão RV, da Silva VJ, Brunoni AR, Hoshi RA, et al. Reference values for short-term resting-state heart rate variability in healthy adults: results from the Brazilian Longitudinal Study of Adult Health-ELSA-Brasil study. Psychophysiol 2018 Jun 02;55(6):e13052. [CrossRef] [Medline]
    40. Lombardi F, Huikuri H, Schmidt G, Malik M, e-Rhythm Study Group of European Heart Rhythm Association. Short-term heart rate variability: easy to measure, difficult to interpret. Heart Rhythm 2018 Oct;15(10):1559-1560. [CrossRef] [Medline]
    41. Shaffer F, McCraty R, Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. Front Psychol 2014 Sep 30;5:1040 [FREE Full text] [CrossRef] [Medline]
    42. Kim H, Cheon E, Bai D, Lee YH, Koo B. Stress and heart rate variability: a meta-analysis and review of the literature. Psychiatry Investig 2018 Mar;15(3):235-245 [FREE Full text] [CrossRef] [Medline]
    43. Holzman JB, Bridgett DJ. Heart rate variability indices as bio-markers of top-down self-regulatory mechanisms: a meta-analytic review. Neurosci Biobehav Rev 2017 Mar;74(Pt A):233-255. [CrossRef] [Medline]
    44. Porges SW. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol 2001 Oct;42(2):123-146. [CrossRef]
    45. Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord 2000 Dec;61(3):201-216. [CrossRef]
    46. Lehrer PM, Gevirtz R. Heart rate variability biofeedback: how and why does it work? Front Psychol 2014 Jul 21;5. [CrossRef]
    47. Lehrer P, Vaschillo E, Vaschillo B. Resonant frequency biofeedback training to increase cardiac variability: rationale and manual for training. Appl Psychophysiol Biofeedback 2000;25(3):177-191. [CrossRef]
    48. Heilman KJ, Handelman M, Lewis G, Porges SW. Accuracy of the StressEraser in the detection of cardiac rhythms. Appl Psychophysiol Biofeedback 2008 Jun 1;33(2):83-89. [CrossRef] [Medline]
    49. Stein PK. Validation of the happify breather biofeedback exercise to track heart rate variability using an optical sensor. Washington University School of Medicine.   URL: https://happify.com/health/results/HLS-05.pdf [accessed 2022-08-03]
    50. Dormal V, Vermeulen N, Mejias S. Is heart rate variability biofeedback useful in children and adolescents? A systematic review. J Child Psychol Psychiatry 2021 Dec 21;62(12):1379-1390. [CrossRef] [Medline]
    51. Pellicano E, Dinsmore A, Charman T. Views on researcher-community engagement in autism research in the United Kingdom: a mixed-methods study. PLoS One 2014 Oct 10;9(10):e109946 [FREE Full text] [CrossRef] [Medline]
    52. Fletcher-Watson S, Adams J, Brook K, Charman T, Crane L, Cusack J, et al. Making the future together: shaping autism research through meaningful participation. Autism 2019 May;23(4):943-953 [FREE Full text] [CrossRef] [Medline]
    53. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat Rev Dis Primers 2020 Jan 16;6(1):5 [FREE Full text] [CrossRef] [Medline]
    54. Mottron L. Should we change targets and methods of early intervention in autism, in favor of a strengths-based education? Eur Child Adolesc Psychiatry 2017 Jul 8;26(7):815-825 [FREE Full text] [CrossRef] [Medline]
    55. DuBois D, Ameis SH, Lai M, Casanova MF, Desarkar P. Interoception in autism spectrum disorder: a review. Int J Dev Neurosci 2016 Aug 03;52(1):104-111. [CrossRef] [Medline]
    56. Lydon S, Healy O, Reed P, Mulhern T, Hughes BM, Goodwin MS. A systematic review of physiological reactivity to stimuli in autism. Dev Neurorehabil 2016 Dec 30;19(6):335-355. [CrossRef] [Medline]
    57. Barbier A, Chen J, Huizinga JD. Autism spectrum disorder in children is not associated with abnormal autonomic nervous system function: hypothesis and theory. Front Psychiatry 2022 Mar 15;13:830234 [FREE Full text] [CrossRef] [Medline]
    58. Cheng Y, Huang Y, Huang W. Heart rate variability in individuals with autism spectrum disorders: a meta-analysis. Neurosci Biobehav Rev 2020 Nov;118:463-471 [FREE Full text] [CrossRef] [Medline]
    59. Social Communication Questionnaire (SCQ). Hogrefe.   URL: https://www.hogrefe.co.uk/shop/social-communication-questionnaire-85199.html [accessed 2014-10-14]
    60. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biological Psychiatry 2010 Jun;67(11):1067-1074. [CrossRef]
    61. Kalinowski A, Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 2016 Jul;111(7):1293-1298. [CrossRef] [Medline]
    62. HeartMath homepage. HeartMath.   URL: https://www.heartmath.com/ [accessed 2014-10-12]
    63. Owner’s Manual. StressEraser®.   URL: https://www.andrews.edu/services/ctcenter/prevention/stress_eraser_manual.pdf [accessed 2022-08-03]
    64. Actiheart 5. CamNtech Ltd.   URL: https://www.camntech.com/actiheart-5/ [accessed 2014-10-14]
    65. Beck Anxiety Inventory. Pearson. 1993.   URL: https://www.pearsonclinical.co.uk/ [accessed 2013-07-11]
    66. Beck Depression Inventory-II. Pearson. 1996.   URL: https://www.pearsonclinical.co.uk/ [accessed 2013-07-11]
    67. Beck Youth Inventories | Second Edition. Pearson. 2005.   URL: https://www.pearsonclinical.co.uk/ [accessed 2013-07-11]
    68. Brooke J. SUS - A quick and dirty usability scale. In: Usability Evaluation In Industry. Boca Raton, Florida: CRC Press; 1996.
    69. Bangor A, Kortum P, Miller, J. Determining what individual SUS scores mean: adding an adjective rating scale. J Usab Stud 2009;4(3):114-123. [CrossRef]
    70. Rutter M, Bailey A, Lord C. Social Communication Questionnaire: WPS; 2003. https://www.hogrefe.co.uk/shop/social-communication-questionnaire-85199.html .
    71. Brown C, Dunn W. Adolescent/Adult Sensory Profile: Pearson; 2002.   URL: https:/​/www.​pearsonclinical.co.uk/​store/​ukassessments/​en/​Store/​Professional-Assessments/​Motor-Sensory/​Adolescent-Adult-Sensory-Profile/​p/​P100009054.​html
    72. van Doorn P. Een vragenlijst voor hyperventilatieklachten. De Psycholoog 1983;18:513-517.
    73. Tarvainen M. Kubios HRV Premium version (ver.3.0.2) users guide. 2016.   URL: https://www.kubios.com/support@kubios.com
    74. Malik M. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996 Mar 01;93(5):1043-1065. [Medline]
    75. Quintana DS, Alvares GA, Heathers JA. Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication. Transl Psychiatry 2016 May 10;6(5):e803 [FREE Full text] [CrossRef] [Medline]
    76. Berntson GG, Bigger JT, Eckberg DL, Grossman P, Kaufmann PG, Malik M, et al. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 1997 Nov;34(6):623-648. [CrossRef] [Medline]
    77. Denver JW, Reed SF, Porges SW. Methodological issues in the quantification of respiratory sinus arrhythmia. Biol Psychol 2007 Feb;74(2):286-294 [FREE Full text] [CrossRef] [Medline]
    78. Nunan D, Sandercock GRH, Brodie DA. A quantitative systematic review of normal values for short-term heart rate variability in healthy adults. Pacing Clin Electrophysiol 2010 Nov;33(11):1407-1417. [CrossRef] [Medline]
    79. Huang C, Gevirtz RN, Onton J, Criado JR. Investigation of vagal afferent functioning using the Heartbeat Event Related Potential. Int J Psychophysiol 2018 Sep;131:113-123. [CrossRef] [Medline]
    80. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 2001 Feb;42(2):241-251. [Medline]
    81. Kushki A, Brian J, Dupuis A, Anagnostou E. Functional autonomic nervous system profile in children with autism spectrum disorder. Mol Autism 2014;5:39 [FREE Full text] [CrossRef] [Medline]
    82. Lang PJ, Bradley MM, Cuthbert BN. ‘International Affective Picture System’ (IAPS): Technical Manual and Affective Ratings. NIMH Center for the Study of Emotion and Attention. Gainsville: University of Florida; 1997.
    83. Sauro J. A Practical Guide to the System Usability Scale: Background, Benchmarks & Best Practices. Scotts Valley, California, US: Createspace Independent Pub; 2011.
    84. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon? Community views and priorities from the United Kingdom. Autism 2014 Oct 30;18(7):756-770 [FREE Full text] [CrossRef] [Medline]
    85. Schiltz H, McIntyre N, Swain-Lerro L, Zajic M, Mundy P. The stability of self-reported anxiety in youth with autism versus ADHD or typical development. J Autism Dev Disord 2017 Dec;47(12):3756-3764 [FREE Full text] [CrossRef] [Medline]
    86. Richa S, Fahed M, Khoury E, Mishara B. Suicide in autism spectrum disorders. Arch Suicide Res 2014 Nov 07;18(4):327-339. [CrossRef] [Medline]
    87. Hirvikoski T, Mittendorfer-Rutz E, Boman M, Larsson H, Lichtenstein P, Bölte S. Premature mortality in autism spectrum disorder. Br J Psychiatry 2016 Mar 02;208(3):232-238. [CrossRef] [Medline]
    88. Harman K. Mastery of Your Anxiety and Panic: Workbook for Primary Care Settings (Treatments That Work) (4th edition). New York: Oxford University Press; 2007.
    89. Reiner R. Integrating a portable biofeedback device into clinical practice for patients with anxiety disorders: results of a pilot study. Appl Psychophysiol Biofeedback 2008 Mar 20;33(1):55-61. [CrossRef] [Medline]
    90. de Bruin EI, van der Zwan JE, Bögels SM. A RCT comparing daily mindfulness meditations, biofeedback exercises, and daily physical exercise on attention control, executive functioning, mindful awareness, self-compassion, and worrying in stressed young adults. Mindfulness (N Y) 2016 Jul 2;7(5):1182-1192 [FREE Full text] [CrossRef] [Medline]
    91. Ming X, Patel R, Kang V, Chokroverty S, Julu PO. Respiratory and autonomic dysfunction in children with autism spectrum disorders. Brain Dev 2016 Feb;38(2):225-232. [CrossRef] [Medline]
    92. Brown SB, Brosschot JF, Versluis A, Thayer JF, Verkuil B. New methods to optimally detect episodes of non-metabolic heart rate variability reduction as an indicator of psychological stress in everyday life. Int J Psychophysiol 2018 Sep;131:30-36. [CrossRef] [Medline]
    93. Wheat AL, Larkin KT. Biofeedback of heart rate variability and related physiology: a critical review. Appl Psychophysiol Biofeedback 2010 Sep 5;35(3):229-242. [CrossRef] [Medline]
    94. Goodman M, Castro N, Sloan M, Sharma R, Widdowson M, Herrera E, et al. A neurovisceral approach to autism: targeting self-regulation and core symptoms using neurofeedback and biofeedback. NeuroRegulation 2018 Mar 31;5(1):9-29. [CrossRef]
    95. Meier NF, Welch AS. Walking versus biofeedback: a comparison of acute interventions for stressed students. Anxiety Stress Coping 2016 Sep 25;29(5):463-478. [CrossRef] [Medline]
    96. Update on NAT’s activities – January 2022. National Autistic Taskforce.   URL: http://nationalautismproject.org.uk/wp-content/uploads/2017/01/autism-dividend-report.pdf [accessed 2022-08-03]
    97. Figueroa C, Aguilera A. The need for a mental health technology revolution in the COVID-19 pandemic. Front Psychiatry 2020;11:523 [FREE Full text] [CrossRef] [Medline]
    98. Van Daele T, Karekla M, Kassianos AP, Compare A, Haddouk L, Salgado J, et al. Recommendations for policy and practice of telepsychotherapy and e-mental health in Europe and beyond. J Psychother Integration 2020 Jun;30(2):160-173. [CrossRef]
    99. Schreibman L, Dawson G, Stahmer AC, Landa R, Rogers SJ, McGee GG, et al. Naturalistic developmental behavioral interventions: empirically validated treatments for autism spectrum disorder. J Autism Dev Disord 2015 Aug 4;45(8):2411-2428 [FREE Full text] [CrossRef] [Medline]
    100. Caldwell YT, Steffen PR. Adding HRV biofeedback to psychotherapy increases heart rate variability and improves the treatment of major depressive disorder. Int J Psychophysiol 2018 Sep;131:96-101. [CrossRef] [Medline]
    101. De Witte NA, Buyck I, Van Daele T. Combining biofeedback with stress management interventions: a systematic review of physiological and psychological effects. Appl Psychophysiol Biofeedback 2019 Jun 2;44(2):71-82. [CrossRef] [Medline]

    ‎
    ASD: autism spectrum disorder
    CONSORT: Consolidated Standards of Reporting Trials
    ECG: electrocardiogram
    HRV: heart rate variability
    PPG: photoplethysmography
    SUS: System Usability Scale

    Edited by A Mavragani; submitted 15.03.22; peer-reviewed by R Gevirtz, V Ritschl; comments to author 18.04.22; revised version received 24.06.22; accepted 30.06.22; published 26.08.22

    Copyright

    ©Helen Coulter, Mark Donnelly, John Mallett, W George Kernohan. Originally published in JMIR Formative Research (https://formative.jmir.org), 26.08.2022.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.